Investigational drug · Phase 2
RO7965032
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "RO7965032"
First trial start
2027
Jan 8, 2027
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RO7965032", any sponsor or status.
Conditions studied
As listed on its trial records.
- Geographic Atrophy Secondary to Age-Related Macular Degeneration
Approved drugs for the same conditions: Wet macular degeneration · Geographic atrophy · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "RO7965032" as an intervention, largest first.
- A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular DegenerationPivotal-lookingRecruiting
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT07851259 · 321 participants (planned) · Start Jan 8, 2027 · Primary completion Aug 21, 2030
Drug: RO7965032; Placebo · For: Geographic Atrophy Secondary to Age-Related Macular Degeneration
Sites: Walnut Creek, California; Winston-Salem, North Carolina; Erie, Pennsylvania · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Geographic Atrophy Secondary to Age-Related Macular Degeneration
- siRNAADX-038, ADX-324Phase 37 trials
ADARx Pharmaceuticals, Inc. · Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1
- APL-3007Phase 21 trial
Apellis Pharmaceuticals, Inc. · Geographic Atrophy Secondary to Age-related Macular Degeneration
- FWY003Phase 21 trial
Novartis · Geographic Atrophy Secondary to Age-related Macular Degeneration
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.